CA3254727A1 - PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS - Google Patents
PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERSInfo
- Publication number
- CA3254727A1 CA3254727A1 CA3254727A CA3254727A CA3254727A1 CA 3254727 A1 CA3254727 A1 CA 3254727A1 CA 3254727 A CA3254727 A CA 3254727A CA 3254727 A CA3254727 A CA 3254727A CA 3254727 A1 CA3254727 A1 CA 3254727A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- methylone
- disorders
- anxiety
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263325757P | 2022-03-31 | 2022-03-31 | |
| US63/325,757 | 2022-03-31 | ||
| US202263328343P | 2022-04-07 | 2022-04-07 | |
| US63/328,343 | 2022-04-07 | ||
| USPCT/US2022/074369 | 2022-08-01 | ||
| PCT/US2022/074369 WO2023015154A1 (en) | 2021-08-06 | 2022-08-01 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| US202363437000P | 2023-01-04 | 2023-01-04 | |
| US63/437,000 | 2023-01-04 | ||
| PCT/US2023/012196 WO2023191952A1 (en) | 2022-03-31 | 2023-02-02 | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3254727A1 true CA3254727A1 (en) | 2023-10-05 |
Family
ID=88203364
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3254727A Pending CA3254727A1 (en) | 2022-03-31 | 2023-02-02 | PSYCHOACTIVE MEDICINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS AND DISORDERS |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP4499066A4 (https=) |
| JP (1) | JP2025510790A (https=) |
| KR (1) | KR20240165982A (https=) |
| CN (1) | CN119095593A (https=) |
| AU (1) | AU2023241546A1 (https=) |
| CA (1) | CA3254727A1 (https=) |
| IL (1) | IL315832A (https=) |
| MX (1) | MX2024012095A (https=) |
| TW (1) | TW202345789A (https=) |
| WO (1) | WO2023191952A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120379978A (zh) * | 2022-10-20 | 2025-07-25 | 创见疗法股份有限公司 | 苯乙胺和卡西酮及其立体异构体与其前体的制备 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
| US8575194B1 (en) * | 2004-08-31 | 2013-11-05 | Jack William Schultz | Treatment methods of cognitive, emotional and mental ailments and disorders |
| EP2931291B1 (en) * | 2012-12-11 | 2021-10-20 | The McLean Hospital Corporation | Xenon treatment as an adjunct to psychotherapy for psychiatric disorders |
| WO2017151980A1 (en) * | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2021257500A1 (en) * | 2020-06-17 | 2021-12-23 | Lobe Sciences Ltd. | Methods and compositions for treating mild traumatic brain injury, post-traumatic stress disorder and mild traumatic brain injury with post traumatic stress disorder |
| JP2024512796A (ja) * | 2021-04-01 | 2024-03-19 | テラン バイオサイエンシーズ インク． | サイケデリック薬およびセロトニン受容体調節因子に関する方法と組成物 |
| MX2024001654A (es) * | 2021-08-06 | 2024-06-28 | Transcend Therapeutics Inc | Medicamentos psicoactivos y su uso para el tratamiento de enfermedades y trastornos psiquiatricos y neurologicos. |
| AU2022330718B2 (en) * | 2021-08-20 | 2026-02-19 | Pharmala Biotech Inc. | Compositions comprising non-racemic mixtures of (r)- and (s)-3,4-methylenedioxymethamphetamine or (r) and (s) n-methyl-1,3-benzodioxolylbutanamine and uses thereof |
| WO2023081899A1 (en) * | 2021-11-05 | 2023-05-11 | Terran Biosciences, Inc. | Isotopically enriched n-methyl-1,3-benzodioxolylbutanamine (mbdb) and stereoisomers thereof |
| EP4426685A4 (en) * | 2021-11-05 | 2026-01-07 | Terran Biosciences Inc | Isotopic salts, crystalline forms, stereoisomers of methylone and ethylone and their methods of use |
| CA3239514A1 (en) * | 2021-12-09 | 2023-06-15 | Matthew J. Baggott | Specialized combinations for mental disorders or mental enhancement |
-
2023
- 2023-02-02 KR KR1020247034657A patent/KR20240165982A/ko active Pending
- 2023-02-02 JP JP2024556474A patent/JP2025510790A/ja active Pending
- 2023-02-02 CN CN202380031652.9A patent/CN119095593A/zh active Pending
- 2023-02-02 WO PCT/US2023/012196 patent/WO2023191952A1/en not_active Ceased
- 2023-02-02 EP EP23781540.2A patent/EP4499066A4/en active Pending
- 2023-02-02 CA CA3254727A patent/CA3254727A1/en active Pending
- 2023-02-02 IL IL315832A patent/IL315832A/en unknown
- 2023-02-02 AU AU2023241546A patent/AU2023241546A1/en active Pending
- 2023-02-06 TW TW112104131A patent/TW202345789A/zh unknown
-
2024
- 2024-09-30 MX MX2024012095A patent/MX2024012095A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024012095A (es) | 2025-01-09 |
| KR20240165982A (ko) | 2024-11-25 |
| IL315832A (en) | 2024-11-01 |
| CN119095593A (zh) | 2024-12-06 |
| WO2023191952A1 (en) | 2023-10-05 |
| JP2025510790A (ja) | 2025-04-15 |
| TW202345789A (zh) | 2023-12-01 |
| EP4499066A4 (en) | 2026-02-18 |
| AU2023241546A1 (en) | 2024-10-17 |
| EP4499066A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11969407B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| TWI553006B (zh) | 依託拉嗪(eltoprazine)於治療與神經或心理疾病有關之認知失能之症狀的用途 | |
| US20230172862A1 (en) | Extended release pharmaceutical compositions of levetiracetam | |
| EP2968220B1 (en) | Methods and compositions for improving cognitive function | |
| AU2023241546A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US20250221957A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| WO2004045718A2 (en) | Treatment of cognitive dysfunctions' | |
| US12295937B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US12343326B2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| US20250332139A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| AU2024284688A1 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| WO2024254190A2 (en) | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders | |
| HK40120411A (zh) | 精神作用药物及其用於治疗精神和神经病状和病症的用途 | |
| HK40112015A (zh) | 精神作用药物及其用於治疗精神和神经病状和病症的用途 | |
| CN118434416A (zh) | 精神作用药物及其用于治疗精神和神经病状和病症的用途 | |
| JP2024508372A (ja) | 注意欠陥／多動性障害の治療又は予防に使用するための化合物 | |
| KR20260053276A (ko) | 향정신성 의약품과 정신 및 신경계 병태 및 장애를 치료하기 위한 이의 용도 | |
| EP4522176A1 (en) | Selective dopamine increase | |
| HK1252154B (zh) | 左乙拉西坦的延时释放药物组合物 | |
| HK1220364B (en) | Methods and compositions for improving cognitive function |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240923 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20250123 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250123 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250123 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250124 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250131 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250210 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250210 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260107 |